April 3

CARB-X partners with Specific Diagnostics to support the development of a rapid accurate test to diagnose life-threatening drug-resistant infections in the blood

(BOSTON, MA) – April 3, 2018 - CARB-X is awarding Specific Diagnostics of Mountain View, CA, up to $1.7 million, with the possibility of up to $1.7 million more based on achievement of project milestones, to support the development of the company's antibiotic susceptibility testing (AST) system, which could be a game-changer in the way drug-resistant infections are diagnosed and treated, resulting in lower health costs and fewer deaths.

January 5

Specific Technologies Appoints Robin Patel, M.D., Mayo Clinic, to Scientific Advisory Board

MOUNTAIN VIEW, Calif., Jan. 5, 2018Specific Technologies (“Specific”) is pleased to announce that Robin Patel, M.D., D(ABMM), chair, Mayo Clinic Division of Clinical Microbiology, Professor of Microbiology and Medicine, and the Elizabeth P. and Robert E. Allen Professor of Individualized Medicine, has been appointed to the company’s Scientific Advisory Board. Dr. Patel, a widely recognized practice leader across microbiology diagnostics, was recently elected president of the American Society for Microbiology.

2017

June 3

MOUNTAIN VIEW, California, June 3, 2017  Specific announces unprecedented ability to determine MIC and ID within 4 hours of positive blood culture, using a low-cost disposable.

Specific Technologies, which has developed a novel paradigm combining the detection and identification (ID) of microorganisms during blood culture, announces today a revolutionary system combining phenotypic AST with ID, performed in 4 hours directly from a positive blood culture sample.  This capability is revealed in a late-breaker abstract accepted by the American Society for Microbiology to be showcased at the ASM Microbe conference. The abstract will be presented on June 3rd at 12:15 – 2:15, on poster number CPHM LB1.

March 15

MOUNTAIN VIEW, California, March 15, 2017Specific Technologies announces the combined faster detection and ID of yeast infection in blood culture

Specific Technologies, which has developed SpecID™, an innovative paradigm for detection and identification of pathogenic microorganisms based on their volatile metabolic signatures, announces today the publication of a study in PLOS ONE detailing the demonstration of the SpecID™ system to detect and identify pathogenic yeasts in simulated blood culture.

March 2

MOUNTAIN VIEW, California, March 2, 2017 — Specific Technologies announces discovery of a CRE signature in E. coli. growing in culture, to be presented at ECCMID global summit in April

Specific Technologies, which has developed a new microbiology diagnostic paradigm combining detection and identification (ID) of microorganisms growing in culture, announces today the discovery of a unique signature for deadly Carbapenem-resistant Enterobacteriaceae (CRE) strains of E. coli.  Specific will present its findings at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), on April 24, 2017, in Vienna, Austria.

February 28

MOUNTAIN VIEW, California, February 28, 2017 — Specific Technologies has been recognized as a National Institute of Allergy and Infectious Diseases (NIAID) Success Story, joining previous distinguished recipients including Illumina.

Specific Technologies, which has developed innovative paradigms for the detection, identification (ID) and antibiotic susceptibility testing (AST) of microorganisms growing in culture, announces today that the Company has been recognized as a “Success Story” by the National Institute of Allergy and Infectious Diseases (NIAID) Small Business Innovation Research (SBIR) program.